Ampersand is using its computationally powered AND-Platform to create next-generation modular medicines designed to effectively target the site of disease without affecting healthy tissue or cells.

Ampersand’s Series B funding will fuel the continued development of its computationally powered Address, Navigate, Determine (AND)™ Platform to program AND-Body™ Therapeutics, a new category ...

Ampersand Capital Partners ("Ampersand"), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, today announced the acquisition of CurTec ...

In addition to vehicle manufacturing, Ampersand operates a cutting-edge, AI-driven battery exchange network. This system efficiently manages 18,000 daily battery charges and swaps.